Fig. 2.

A CV outcomes/mortality by baseline metformin use (adjusted analysis); B Kaplan–Meier curves of primary outcome by baseline metformin. Figures (A) and (B) compare semaglutide with placebo. ^*n-numbers are based on the FAS; the number of subjects included for each endpoint analysis differed according to data availability. A Analyses for SUSTAIN 6 and PIONEER 6 are based on a Cox proportional hazards model with treatment (semaglutide, placebo) by metformin subgroup as fixed factors, stratified by trial and CV risk group (established CVD and/or CKD vs risk factors), and adjusted by baseline variables: sex (male vs female), smoker (current smoker, previous smoker, never smoked), previous MI/stroke/TIA (yes vs no), region (European Union, North America, other), antidiabetic treatment (yes vs no), diabetes duration, eGFR-MDRD and age. CI confidence interval, CKD chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, eGFR-MDRD estimated glomerular filtration rate-modification of diet in renal disease, FAS full analysis set, HbA_1c glycated hemoglobin, HHF hospitalization for heart failure, HR hazard ratio (semaglutide vs placebo), MACE major adverse cardiovascular event, MET metformin, MI myocardial infarction, TIA transient ischemic attack